Open AccessThis article is
- freely available
Bevacizumab for Glioblastoma—A Promising Drug or Not?
Department of Neurosurgery, Kyorin University Faculty of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan
Department of Neuro-Oncology/Neurosurgery, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama-ken 350-1298, Japan
* Author to whom correspondence should be addressed.
Received: 11 October 2013 / Accepted: 24 October 2013 / Published: 7 November 2013
Abstract Two double blind, placebo-controlled, and randomized phase III studies were conducted, and the results including OS’s were reported at the ASCO Meeting in June 2013, which was the beginning of confusion surrounding this topic. This is a review article not only summarizing the previous evidence, but also looking beyond.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Share & Cite This Article
MDPI and ACS Style
Nagane, M.; Nishikawa, R. Bevacizumab for Glioblastoma—A Promising Drug or Not? Cancers 2013, 5, 1456-1468.
View more citation formats
Nagane M, Nishikawa R. Bevacizumab for Glioblastoma—A Promising Drug or Not? Cancers. 2013; 5(4):1456-1468.
Nagane, Motoo; Nishikawa, Ryo. 2013. "Bevacizumab for Glioblastoma—A Promising Drug or Not?" Cancers 5, no. 4: 1456-1468.
Notes: Multiple requests from the same IP address are counted as one view.
For more information on the journal, click here
[Return to top]